In direct contrast, @ARPA_H launched a program to develop at- home testing for early detection of 30+ cancers
@erictopol
-
Cancer Hijacks Existing Biological Processes Innovation Model
By
–
“Cancer doesn’t really invent anything new— it just hijacks processes that already exist.”—
@michelle_monje -
Cancer Treatment Breakthroughs: New AI-Driven Discovery Possibilities
By
–
Cancer has the remarkable ability to hijack our cells, mitochondria, nervous system and blood vessels. A surge of recent discoveries is also raising new treatment possibilities. In the new edition of Ground Truths
(Link in my profile d/t X suppression) -
Lancet Editorial Criticizes Direct-to-Consumer Medical Testing
By
–
This week's @TheLancet editorial, a hard stance against direct-to-consumer medical testing https://
thelancet.com/journals/lance
t/article/PIIS0140-6736(24)01924-X/fulltext
… -
Yuval Harari’s NEXUS Book Criticized as AI Apocalypse Warning
By
–
A scathing review of @harari_yuval
's new book, NEXUS, summed up as an "#AI Apocalypse," demeaning, calling out our naivety.
I'm reading it now, asked Yuval to do an interview, but his people said he's too busy. https://
wsj.com/arts-culture/b
ooks/nexus-review-prognosis-apocalyptic-b888e741?mod=books_more_article_pos10
… by @DrDominicGreen -
IDH-Mutation Pill Breakthrough: $480K Annual Cost Challenge
By
–
There's never been a successful Rx mutation-directed pill approved for brain cancer (gliomas and astrocytomas, grade 2) that extends progression-free survival, until the one directed vs IDH mutations came along. Unfortunately, its price is $480K/year https://
statnews.com/2024/09/13/vor
anigo-servier-brain-cancer-breakthrough/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9DWCCc1Ks1m4ePfKrA9eh5KuIbxXyRQ6Z8kJbcMA1R_X2AF0P3L8-bZ_ZErbz7UnVirnkrwg4a01d4C2k1RSYLVARWlg&_hsmi=324444687&utm_content=324444687&utm_source=hs_email
… -
Biopharma Competition for Rare Cardiac Amyloidosis Treatment Market
By
–
Biopharma's focus on rare conditions and financial reward, exemplified:
A rare disease—primary AATR cardiac amyloidosis—is the subject of an emerging 3-way treatment competition for many $ billions per year. https://
wsj.com/health/pharma/
the-brawl-taking-shape-over-pfizers-multibillion-dollar-heart-monopoly-43a220c2?mod=Searchresults_pos1&page=1
… @pfizer @BridgeBioPharma @Alnylam -
OpenAI Strawberry Excels in AgentClinic Benchmarking
By
–
Strawberry @OpenAI is looking quite good in benchmarking by AgentClinic! https://
agentclinic.github.io -
DebunkBot: AI Chatbot Fights Conspiracy Theories
By
–
More on DebunkBot
gift link https://
nytimes.com/2024/09/12/hea
lth/chatbot-debunk-conspiracy-theories.html?unlocked_article_code=1.KU4.HRJ9.wZoqVG75yMmK&smid=url-share
…
by @teddyrosenbluth -
RCT Methodology Versus Observational Studies in AI Research
By
–
Agree to be skeptical. Also RCT vs hodgepodge observational study, but it’s an interesting report